US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Generate Biomedicines

15.78

+0.50503.31%

Volume:659.01K

Turnover:10.20M

Market Cap:2.02B

PE:-4.81

High:15.93

Open:15.12

Low:14.93

Close:15.27

52wk High:22.67

52wk Low:11.00

Shares:128.19M

Float Shares:60.29M

Volume Ratio:0.30

T/O Rate:1.09%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.2762

EPS(LYR):-4.9816

ROE:-81.72%

ROA:-34.63%

PB:4.43

PE(LYR):-3.17

Loading ...

Overview Company News Filings

A Look At Generate Biomedicines (GENB) Valuation After Nvidia’s US$10.4 Million Investment

Simply Wall St.

U.S. Small Caps Close Mixed As LiveRamp Holdings Leads, Generate Biomedicines Lags

Generate Biomedicines Is Maintained at Overweight by Morgan Stanley

Generate Biomedicines, Inc. (GENB) Receives a Buy from Morgan Stanley

Morgan Stanley Lifts Price Target on Generate Biomedicines to $22 From $20, Keeps Overweight Rating

MT Newswires Live

Piper Sandler Sticks to Their Buy Rating for Generate Biomedicines, Inc. (GENB)

Generate Biomedicines Is Maintained at Buy by HC Wainwright & Co.

Generate Biomedicines reports Q1 revenue $7.22M, consensus $4.75M

Earnings Flash (GENB) Generate Biomedicines Posts Q1 Net Loss $61.4M, vs. FactSet Est of $61.2M Loss

MT Newswires Live

Generate Biomedicines : Believes Existing Cash, Cash Equivalents, Marketable Securities Will Be Sufficient to Fund Operations Into First Half of 2028

THOMSON REUTERS

Generate Biomedicines Inc - Q1 Revenue $7.2 Mln

THOMSON REUTERS

Generate Biomedicines Inc: Expects to Require Additional Capital to Support Long-Term Operations

THOMSON REUTERS

Press Release: Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update

Generate Biomedicines Q1 FY26 net loss widens to $61.7 million; revenue falls to $7.2 million

Generate Biomedicines Initiated at Buy by HC Wainwright & Co.

Generate Biomedicines initiated with a Buy at H.C. Wainwright

Buy Rating on Generate Biomedicines Driven by Differentiated Pipeline, GB-0895 Asthma Opportunity, and AI-Enabled Protein Platform

Generate Biomedicines publishes corporate presentation on programmable biology drug design platform

BUZZ-Morgan Stanley bullish on Generate Biomedicines, cites strength of lead asthma drug

Generate Biomedicines: Differentiated AI-Driven Protein Platform with GB-0895 Asthma Lead and Emerging Oncology Upside Justifies Buy Rating

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/GENB/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GENB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GENB\",,,,,undefined,":{"symbol":"GENB","market":"US","secType":"STK","nameCN":"Generate Biomedicines","latestPrice":15.775,"timestamp":1788286099533,"preClose":15.27,"halted":0,"volume":659010,"delay":0,"changeRate":0.033071381794368096,"floatShares":60288200,"shares":128192484,"eps":-3.27625,"marketStatus":"Trading","change":0.505,"latestTime":"09-01 14:08:48 EDT","open":15.12,"high":15.93,"low":14.93,"amount":10203915.11403,"amplitude":0.065488,"askPrice":15.79,"askSize":75,"bidPrice":15.76,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-3.27625,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788292800000},"marketStatusCode":2,"adr":0,"listingDate":1772168400000,"exchange":"NASDAQ","adjPreClose":15.27,"preHourTrading":{"tag":"盘前","latestPrice":15,"preClose":15.27,"latestTime":"09:20 EDT","volume":8136,"amount":123796.96919999999,"timestamp":1788268834987,"change":-0.27,"changeRate":-0.017682,"amplitude":0.045318},"postHourTrading":{"tag":"盘后","latestPrice":15.35,"preClose":15.27,"latestTime":"19:44 EDT","volume":9271,"amount":140579.348,"timestamp":1788219881115,"change":0.08,"changeRate":0.005239,"amplitude":0.019646},"volumeRatio":0.300854},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GENB\",,,,,undefined,":{"symbol":"GENB","floatShares":60288200,"roa":"-34.63%","roe":"-81.72%","lyrEps":-4.981642,"volumeRatio":0.300854,"shares":128192484,"dividePrice":0,"high":15.93,"amplitude":0.065488,"preClose":15.27,"low":14.93,"week52Low":11,"pbRate":"4.43","psRate":"76.36","week52High":22.6699,"institutionHeld":0,"latestPrice":15.775,"committee":-0.973684,"eps":-3.27625,"divideRate":0,"volume":659010,"delay":0,"ttmEps":-3.27625,"open":15.12,"prevYearClose":16,"prevWeekClose":15.33,"prevMonthClose":15.27,"prevQuarterClose":16.87,"fiveDayClose":20.38,"twentyDayClose":14.28,"sixtyDayClose":12.87},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GENB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-06","symbol":"GENB","fiscalQuarterEnding":"2026/06","expectedEps":-0.48,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"pre","actualEps":-0.52},{"market":"US","date":"2026-05-07","symbol":"GENB","fiscalQuarterEnding":"2026/03","expectedEps":-0.48,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"pre","actualEps":-1.07}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GENB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GENB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1667,"buy":0.8333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8333,"analysts":6,"updateTime":1782532800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GENB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GENB","date":"2026-08-31","current":-4.700496,"percent":0.309524,"low":-11.002825,"twenty":-8.698603,"median":-7.976268,"eighty":-7.531161,"high":-6.883628,"avg":-8.152533,"sd":0.750188,"marketCap":1967642843},"quantilePoints":[{"date":"2026-02-27","current":-10.037721,"twenty":-10.037721,"median":-10.037721,"eighty":-10.037721,"marketCap":2039203216},{"date":"2026-03-06","current":-7.810602,"twenty":-7.936073,"median":-7.722772,"eighty":-7.484376,"marketCap":1586755002},{"date":"2026-03-13","current":-8.331309,"twenty":-7.979988,"median":-7.660036,"eighty":-7.484376,"marketCap":1692538669},{"date":"2026-03-20","current":-7.710225,"twenty":-7.979988,"median":-7.68513,"eighty":-7.484376,"marketCap":1566362970},{"date":"2026-03-27","current":-8.061545,"twenty":-7.979988,"median":-7.697677,"eighty":-7.484376,"marketCap":1637735082},{"date":"2026-04-02","current":-8.350129,"twenty":-7.996299,"median":-7.697677,"eighty":-7.419131,"marketCap":1696362175},{"date":"2026-04-10","current":-7.233433,"twenty":-7.996299,"median":-7.647489,"eighty":-7.419131,"marketCap":1469500817},{"date":"2026-04-17","current":-7.910979,"twenty":-8.036451,"median":-7.697677,"eighty":-7.419131,"marketCap":1607147034},{"date":"2026-04-24","current":-8.067818,"twenty":-8.0628,"median":-7.732183,"eighty":-7.42164,"marketCap":1639009584},{"date":"2026-05-01","current":-7.923526,"twenty":-8.036451,"median":-7.810602,"eighty":-7.471829,"marketCap":1609696038},{"date":"2026-05-08","current":-8.522653,"twenty":-8.180743,"median":-7.816876,"eighty":-7.489394,"marketCap":1731410980},{"date":"2026-05-15","current":-8.844872,"twenty":-8.266063,"median":-7.84197,"eighty":-7.500687,"marketCap":1971654609},{"date":"2026-05-22","current":-8.039526,"twenty":-8.266063,"median":-7.83256,"eighty":-7.486839,"marketCap":1792130926},{"date":"2026-05-29","current":-7.527711,"twenty":-8.282375,"median":-7.816876,"eighty":-7.489371,"marketCap":1678039615},{"date":"2026-06-05","current":-8.453579,"twenty":-8.282375,"median":-7.810602,"eighty":-7.474106,"marketCap":1884429514},{"date":"2026-06-12","current":-7.435699,"twenty":-8.229473,"median":-7.788352,"eighty":-7.435629,"marketCap":1657528818},{"date":"2026-06-18","current":-7.976268,"twenty":-8.211907,"median":-7.788092,"eighty":-7.435594,"marketCap":1778029753},{"date":"2026-06-26","current":-9.442705,"twenty":-8.343203,"median":-7.810602,"eighty":-7.4449,"marketCap":2104920587},{"date":"2026-07-02","current":-9.488711,"twenty":-8.508838,"median":-7.810602,"eighty":-7.463837,"marketCap":2115175986},{"date":"2026-07-10","current":-9.040154,"twenty":-8.869967,"median":-7.84197,"eighty":-7.484992,"marketCap":2015185848},{"date":"2026-07-17","current":-7.855502,"twenty":-8.85402,"median":-7.855502,"eighty":-7.488094,"marketCap":1751109331},{"date":"2026-07-24","current":-7.953265,"twenty":-8.801131,"median":-7.883241,"eighty":-7.493159,"marketCap":1772902053},{"date":"2026-07-31","current":-8.06828,"twenty":-8.626167,"median":-7.861253,"eighty":-7.503197,"marketCap":1798540550},{"date":"2026-08-07","current":-7.489636,"twenty":-8.522653,"median":-7.910979,"eighty":-7.503197,"marketCap":1780593602},{"date":"2026-08-14","current":-8.114449,"twenty":-8.453579,"median":-7.917253,"eighty":-7.52196,"marketCap":1929137113},{"date":"2026-08-21","current":-8.632737,"twenty":-8.626167,"median":-7.947085,"eighty":-7.52196,"marketCap":2052355451},{"date":"2026-08-28","current":-8.513962,"twenty":-8.702922,"median":-7.964766,"eighty":-7.527711,"marketCap":2024117915},{"date":"2026-08-31","current":-8.276414,"twenty":-8.698603,"median":-7.976268,"eighty":-7.531161,"marketCap":1967642843}],"updateTime":1788274201609},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GENB\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2637836082","title":"A Look At Generate Biomedicines (GENB) Valuation After Nvidia’s US$10.4 Million Investment","url":"https://stock-news.laohu8.com/highlight/detail?id=2637836082","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637836082?lang=en_us&edition=fundamental","pubTime":"2026-05-22 11:34","pubTimestamp":1779420874,"startTime":"0","endTime":"0","summary":"Nvidia’s recent US$10.4 million investment in Generate Biomedicines (GENB) has drawn fresh attention to the AI-focused biotech, as investors assess what this backing could mean for its drug development pipeline.\nSee our latest analysis for Generate Biomedicines.\nThe Nvidia investment comes after a volatile stretch for Generate Biomedicines, with a 1-day share price return of 7.37% to US$13.98, a 30-day share price return of 10.34% and a year to date share price return of 10.51%. This comes...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-genb/generate-biomedicines/news/a-look-at-generate-biomedicines-genb-valuation-after-nvidias","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-genb/generate-biomedicines/news/a-look-at-generate-biomedicines-genb-valuation-after-nvidias","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2456880835.USD","SG9999018857.SGD","LU2491050071.SGD","LU0011850046.USD","IE00BHPRN162.USD","LU2491050154.USD","IE00BK4W5L77.USD","LU2125909247.SGD","LU1989772923.USD","LU0265550359.USD","LU0823434583.USD","LU0029864427.USD","LU2462591277.SGD","SG9999017495.SGD","LU2602419157.SGD","LU1718418525.SGD","LU0823414478.USD","LU0965509283.SGD","LU2097344431.USD","LU1852331112.SGD","LU0708995401.HKD","LU0289739343.SGD","BK4585","LU1629891620.HKD","LU0985320562.USD","LU2065169927.USD","LU1992135399.USD","IE000ITXATA3.USD","LU0175139822.USD","LU1674673428.USD","IE00BMPRXN33.USD","LU0861579265.USD","LU0143551892.USD","LU2360106780.USD","IE0004445015.USD","LU0528227936.USD","LU0820561818.USD","DIPS","IE000YTNTUN2.SGD","IE00B775H168.HKD","IE00BMPRXQ63.HKD","LU1720051017.SGD","IE00BQXX3F31.USD","LU1778281490.HKD","LU0719512351.SGD","LU1037948897.HKD","LU0077335932.USD","LU2750360997.AUD","LU0289961442.SGD","LU1623119135.USD","LU2237957902.USD","HK0000819398.USD","LU2394011477.USD","LU0466842654.USD","LU2054465674.USD","LU2592432038.USD","LU1145028129.USD","LU2272731782.SGD","HK0000306701.USD","LU0266013472.USD","LU2125154778.USD","LU2089283258.USD","LU1323610961.USD","IE000W1ABFV2.USD","LU0964807845.USD","SGXZ81514606.USD","NVYY","LU0096362180.USD","LU2247934214.USD","IE00BJJMRX11.SGD","LU0210536198.USD","IE0001KFT4U8.USD","LU1868836757.USD","LU1923623000.USD","LU1923622291.USD","LU1366333091.USD","NVDD","SG9999002224.SGD","LU1066053197.SGD","LU2896262040.SGD","LU2106854487.HKD","LU0080751232.USD","LU2543165471.USD","LU1496350171.SGD","LU0234570918.USD","LU2023250330.USD","NVDB","LU1267930730.SGD","LU2264538146.SGD","SG9999002232.USD","IE00BKPKM429.USD","LU1815333072.USD","LU1791710582.SGD","LU1267930490.SGD","LU1645745479.HKD","BK4579","IE00BK4W5M84.HKD","SG9999014898.SGD","IE00BJJMRY28.SGD","LU2505996509.AUD","LU0057025933.USD","LU2361045086.USD","LU0210533765.USD","LU2100268510.USD","LU2077746001.SGD","GENB","BK4534","LU1153585028.USD","LU0354030511.USD","LU0289960550.SGD","LU1242518931.SGD","LU2063271972.USD","LU1674673691.USD","NVD2.UK","LU1951198990.SGD","BK4592","LU1803068979.SGD","LU1366192091.USD","LU1670756490.USD","LU0511384066.AUD","LU2237957811.SGD","HK0000320223.HKD","SGXZ51526630.SGD","LU2065171402.SGD","IE00BDRTCR15.USD","LU0211327993.USD","LU1935042488.USD","LU2065171311.SGD","LU0390134368.USD","LU1868836591.USD","SG9999015945.SGD","LU0444973449.USD","LU0345770993.USD","IE00BFSS7M15.SGD","LU1861215975.USD","IE0004091025.USD","LU2023251221.USD","LU1691799644.USD","LU0642271901.SGD","LU0265550946.USD","SG9999014575.USD","NVDG","BK4549","LU1244550221.USD","LU0942090050.USD","LU1084165304.USD","LU1066051811.HKD","SG9999014914.USD","LU0345768153.USD","IE00B3SWFQ91.USD","LU1242518857.USD","IE0034235303.USD","LU1066051225.USD","BK4554","LU1429558221.USD","IE0003U64NQ7.SGD","LU2361044949.HKD","LU2125909593.SGD","LU1992135472.HKD","LU2111349929.HKD","LU2191332357.HKD","LU1814569148.SGD","IE00BQXX3C00.GBP","LU0979878070.USD","LU1035775433.USD","BK4141","LU2357305700.SGD","LU2272731600.USD","LU1935042215.USD","LU0081259029.USD","LU0310799852.SGD","LU2430703251.USD","LU1815336760.USD","LU0708994859.HKD","LU2471134952.CNY","LU0323591593.USD","BK4550","IE00BJTD4V19.USD","LU0256863902.USD","LU2461242641.AUD","NVD","IE00B3S45H60.SGD","LU2125154935.USD","LU1804176565.USD","LU2360107168.USD","SG9999014906.USD","IE00BN29S564.USD","LU2244417387.USD","LU0158827948.USD","LU0107464264.USD","LU0787776722.HKD","LU0640476718.USD","LU0072462426.USD","LU0868494708.USD","LU1069344957.HKD","LU2322448791.USD","LU1791710400.SGD","LU0094547139.USD","LU0170899867.USD","LU0274383776.USD","BK4529","BK4527","LU0788109477.HKD","LU2458330169.SGD","NVII","SG9999001424.SGD","LU2271345857.HKD","LU2462591350.SGD","LU2237438978.USD","LU2746668974.SGD","LU0069063385.USD","LU2272731865.HKD","NVDU","LU0256863811.USD","LU0124676726.USD","LU1267930573.SGD","LU2322448957.HKD","BK4548","LU1244550494.USD","LU1934455277.USD","BK4139","BK4543","SG9999015978.USD","SNVD.UK","LU0225283273.USD","2NVD.UK","LU1821325948.USD","LU0965509101.SGD","LU2083900584.USD","NVDA","HK0000304797.USD","LU2860962120.EUR","LU0308772762.SGD","LU0724617625.USD","LU1496350502.SGD","LU2326559502.SGD","LU2360032135.SGD","LU0127658192.USD","SGXZ99366536.SGD","LU0823434740.USD","LU1935042991.SGD","3NVD.UK","LU2473716301.USD","IE00BMPRXR70.SGD","IE00B19Z8X17.USD","LU2458330243.SGD","LU0672654240.SGD","LU0494093205.USD","LU0957791311.USD","LU0320765059.SGD","SG9999004303.SGD","BK4567","IE00BDCRKT87.USD","LU2092627202.USD","07788","IE0034235295.USD","LU2168564149.EUR","LU2125909759.SGD","LU1232071149.USD","LU1934455194.USD","LU2023250504.SGD","LU1935043023.USD","LU1989764664.SGD","SG9999014567.USD","IE0004445239.USD","LU0965509010.AUD","LU0823421416.USD","IE00BZ1G4Q59.USD","LU0079474960.USD","LU1974910355.USD","BK4532","BK4551","LU2471134523.USD","LU0689626769.HKD","LU1868837136.USD","NVD3.UK","LU0276348264.USD","LU0472753341.HKD","LU1400636574.HKD","SG9999014559.SGD","LU0957808578.USD","LU2463028550.USD","BK4503","LU1280957306.USD","LU1721428933.USD","BK4581","LU0157215616.USD","LU2089284900.SGD","LU2430703178.SGD","NVDO","IE00B4JS1V06.HKD","LU0943347566.SGD","LU2242649171.HKD","BK4598","LU2089985449.USD","BK4605","LU0061474960.USD","LU1699723380.USD","LU1400636657.SGD","HK0000532082.HKD","LU1951200564.SGD","IE00B3M56506.USD","LU2028103732.USD","LU1923622614.USD","LU1861220033.SGD","HK0000914660.USD","HK0000320264.USD","LU1861127337.USD","LU2491049909.HKD","LU0820562030.AUD","BK4533","IE00B7KXQ091.USD","LU0238689110.USD","LU2087621335.USD","LU0347712357.USD","LU2168564065.EUR","LU0109392836.USD","LU1934455863.HKD","SGXZ23171101.USD","IE00B1XK9C88.USD","LU0158827781.USD","LU0198837287.USD","LU0316494557.USD","LU0097036916.USD","LU0354030438.USD","LU0353189680.USD","LU2250418816.HKD","LU1119994496.HKD","LU0061475181.USD","LU2265009873.SGD","LU1261432733.SGD","LU1127390331.HKD","LU0203202063.USD","IE00BZ199S13.USD","LU2092937148.SGD","IE0005OL40V9.USD","LU0786609619.USD","LU2242650005.HKD","LU2471134796.USD","LU2746668461.USD","LU0820561909.HKD","LU0823414551.USD","LU2552382215.SGD","LU0348723411.USD","LU0476273544.USD","LU2168563687.JPY","LU2168564222.USD","LU2487616109.SGD","LU1839511570.USD","LU1868836914.USD","SG9999000418.SGD","SG9999015341.SGD","LU2999663052.SGD","LU2087625088.SGD","NVDQ","LU2954938101.SGD","IE0009G5SDU7.USD","LU1917777945.USD","LU0251132253.USD","LU0557290698.USD","LU0106261372.USD","LU3102509885.SGD","LU1064131342.USD","LU1571399168.USD","BK4587","SG9999015358.SGD","NVDL","LU2286300806.USD","IE00BYXW3230.USD","IE000KEQY171.SGD","LU1244550577.SGD","LU0203201768.USD","LU0310800379.SGD","LU1316542783.SGD","LU0082616367.USD","IE00B775SV38.USD","SG9999015986.USD","ANV","LU0070217475.USD","LU1116320737.USD","LU0154236417.USD","LU0342679015.USD","LU0128525929.USD","LU0187121727.USD","LU1983260115.SGD","LU1935043536.SGD","LU0061474705.USD","LU1435385759.SGD","LU2430703095.HKD","LU1868837300.USD","LU0868494617.USD","LU2417539215.USD","LU1551013342.USD","LU2047632596.USD","LU2213496289.HKD","LU0965508806.USD","LU2413666699.HKD","LU2505996681.GBP","IE00B4YYXB79.USD","LU2211815571.USD","LU0683600562.USD","IE00BJTD4N35.SGD","LU0053666078.USD","LU1548497426.USD","LU2403377893.USD","IE00BKDWB100.SGD","LU0345770308.USD","NVDS","LU2108987350.USD","HK0000306685.HKD","IE00BQXX3D17.EUR","LU0345769128.USD","07388","LU1914381329.SGD","LU2452424414.USD","IE0009356076.USD","BK4612","BK4614","LU0444971666.USD","IE00BJLML261.HKD","LU2249611893.SGD","LU2552382132.HKD","LU2756315318.SGD","IE00B19Z9505.USD","NVDX","LU2756315664.SGD","SG9999018865.SGD","LU1202635105.USD","LU2357125470.USD","LU1712237335.SGD","LU2236285917.USD","LU1066051498.USD","LU2381873111.SGD","HK0000914686.HKD","LU2552382058.USD","LU1037948541.HKD","LU0889565833.HKD","LU0133085943.USD","SG9999014880.SGD","LU0211328371.USD","LU0174119429.USD","IE00BFSS8Q28.SGD","BK4608","HK0000304805.HKD","BK4588","LU1989764748.USD","LU1400636491.USD","LU0056508442.USD","LU2294711713.HKD","LU2361044865.SGD","LU0006306889.USD","LU0823421333.USD","LU1720051108.HKD","IE00BD6J9T35.USD","LU0215105999.USD","IE0034235188.USD","LU0234572021.USD","LU2433249047.HKD","LU0689472784.USD","LU2637965513.SGD","LU2420271590.USD","NVDW","LU0267386448.USD","SG9999015952.SGD","LU1116320901.HKD","LU2125909916.SGD","LU2750360641.GBP","LU1551013425.SGD","LU0048584097.USD","LU0882574139.USD","SGXZ31699556.SGD","LU1642822529.SGD","IE00BKVL7J92.USD","GB00BDT5M118.USD","LU0096364046.USD","LU1633808545.USD","SG9999014542.SGD","LU0353189763.USD","LU0109391861.USD","IE00BWXC8680.SGD","LU2168564495.EUR","LU2065170008.USD","LU0417517546.SGD","LU2290526834.HKD","NVDS.UK","LU0345768740.USD","NVDY","NVIW.SI","IE00B19Z8W00.USD","IE00B5949003.HKD","LU2413666426.HKD","LU2506951792.HKD","LU0345769631.USD","LU2097344357.USD","LU2462157665.USD","LU2471134879.HKD","LU1988902786.USD","LU2931357623.SGD","LU1989772840.SGD","IE0004086264.USD","LU0210528500.USD","IE00B1BXHZ80.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636009586","title":"U.S. Small Caps Close Mixed As LiveRamp Holdings Leads, Generate Biomedicines Lags","url":"https://stock-news.laohu8.com/highlight/detail?id=2636009586","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636009586?lang=en_us&edition=fundamental","pubTime":"2026-05-19 04:21","pubTimestamp":1779135660,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of small-cap companies were mixed Monday, as the Russell 2000 Index declined 0.7%, while the S&P Small Cap 600 Index was up 0.3%.Among companies with a market value of $1 billion to $6.7 billion, Generate Biomedicines Inc. was the biggest laggard during the session, dropping 19%, followed by shares of Rackspace Technology Inc., which dropped 18%. Shares of FuelCell Energy Inc. dropped 17%, Aehr Test Systems shares plunged 16%, and Lightwave Logic Inc. plunged 15%.LiveRamp Holdings Inc. was the best performer, surging 27%, followed by T1 Energy Inc., which surged 23%. Genius Sports Ltd. shares surged 22%, Brady Corp. Cl A surged 19%, and shares of AEVEX Corp. Cl A surged 15%.Major stock indexes in the U.S. ended Monday mixed as the Nasdaq Composite Index fell 0.5%. Meanwhile, the S&P 500 Index fell 0.1%, and the Dow Jones Industrial Average added 0.3%.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635742365","title":"Generate Biomedicines Is Maintained at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2635742365","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635742365?lang=en_us&edition=fundamental","pubTime":"2026-05-15 01:25","pubTimestamp":1778779500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GENB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 14, 2026 13:25 ET (17:25 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635749547","title":"Generate Biomedicines, Inc. (GENB) Receives a Buy from Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2635749547","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635749547?lang=en_us&edition=fundamental","pubTime":"2026-05-14 23:16","pubTimestamp":1778771795,"startTime":"0","endTime":"0","summary":"In a report released today, Sean Laaman from Morgan Stanley maintained a Buy rating on Generate Biomedicines, Inc., with a price target of $22.00. ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/generate-biomedicines-inc-genb-receives-a-buy-from-morgan-stanley-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/generate-biomedicines-inc-genb-receives-a-buy-from-morgan-stanley-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0006306889.USD","LU0528227936.USD","LU0225283273.USD","LU0795875086.SGD","LU0912757837.SGD","LU1548497426.USD","LU1989772923.USD","IE00BZ1G4Q59.USD","LU1720051108.HKD","BK4581","LU0234570918.USD","LU1791710582.SGD","LU2347655156.SGD","LU0390134368.USD","LU1244550221.USD","LU1732800096.USD","LU2271345857.HKD","LU1074936037.SGD","LU0158827781.USD","IE00BKVL7J92.USD","LU0267386448.USD","LU2357305700.SGD","LU1989772840.SGD","LU1244550577.SGD","BK4139","LU2089283258.USD","BK4585","BK4127","LU2111349929.HKD","LU0098860793.USD","LU1363072403.SGD","LU0320765646.SGD","LU0882574139.USD","BK4588","LU0795875169.SGD","LU2133065610.SGD","LU1791710400.SGD","LU0971096721.USD","LU1988902786.USD","BK4534","BK4516","LU1244550494.USD","LU2264538146.SGD","LU2023251221.USD","LU1668664300.SGD","LU2028103732.USD","LU2089284900.SGD","LU0106261372.USD","LU1162221912.USD","GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635719286","title":"Morgan Stanley Lifts Price Target on Generate Biomedicines to $22 From $20, Keeps Overweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2635719286","media":"MT Newswires Live","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635719286?lang=en_us&edition=fundamental","pubTime":"2026-05-14 19:04","pubTimestamp":1778756658,"startTime":"0","endTime":"0","summary":"Generate Biomedicines (GENB) has an average rating of buy and mean price target of $25.40, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633339451","title":"Piper Sandler Sticks to Their Buy Rating for Generate Biomedicines, Inc. (GENB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633339451","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633339451?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:59","pubTimestamp":1778245186,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Generate Biomedicines, Inc. today and set a price target of $24.00. Tenthoff cover...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-their-buy-rating-for-generate-biomedicines-inc-genb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-their-buy-rating-for-generate-biomedicines-inc-genb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633945500","title":"Generate Biomedicines Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2633945500","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633945500?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:11","pubTimestamp":1778242260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GENB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 08, 2026 08:11 ET (12:11 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633159146","title":"Generate Biomedicines reports Q1 revenue $7.22M, consensus $4.75M","url":"https://stock-news.laohu8.com/highlight/detail?id=2633159146","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633159146?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:16","pubTimestamp":1778152597,"startTime":"0","endTime":"0","summary":"“We saw strong progress in the first quarter across our clinical pipeline, next generation of therapeutic programs, and advancing our platform,” sa...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/generate-biomedicines-reports-q1-revenue-7-22m-consensus-4-75m-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/generate-biomedicines-reports-q1-revenue-7-22m-consensus-4-75m-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633111704","title":"Earnings Flash (GENB) Generate Biomedicines Posts Q1 Net Loss $61.4M, vs. FactSet Est of $61.2M Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2633111704","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633111704?lang=en_us&edition=fundamental","pubTime":"2026-05-07 18:22","pubTimestamp":1778149353,"startTime":"0","endTime":"0","summary":"Earnings Flash (GENB) Generate Biomedicines Posts Q1 Net Loss $61.4M, vs. FactSet Est of $61.2M Loss","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633770117","title":"Generate Biomedicines : Believes Existing Cash, Cash Equivalents, Marketable Securities Will Be Sufficient to Fund Operations Into First Half of 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2633770117","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633770117?lang=en_us&edition=fundamental","pubTime":"2026-05-07 18:17","pubTimestamp":1778149047,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nTUA7TQMZK:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GENB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633707117","title":"Generate Biomedicines Inc - Q1 Revenue $7.2 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2633707117","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633707117?lang=en_us&edition=fundamental","pubTime":"2026-05-07 18:17","pubTimestamp":1778149047,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nTUA7TQMZK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GENB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633705117","title":"Generate Biomedicines Inc: Expects to Require Additional Capital to Support Long-Term Operations","url":"https://stock-news.laohu8.com/highlight/detail?id=2633705117","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633705117?lang=en_us&edition=fundamental","pubTime":"2026-05-07 18:17","pubTimestamp":1778149047,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nTUA7TQMZK:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GENB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633248117","title":"Press Release: Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2633248117","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633248117?lang=en_us&edition=fundamental","pubTime":"2026-05-07 18:17","pubTimestamp":1778149020,"startTime":"0","endTime":"0","summary":"-- SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 . -- Clinical trial sites activated for GB-4362 ; first. patient dosing is expected in mid-2026; program has received FDA Fast. -- First patient dosing is expected in the second half of 2026 for GB-5267. SOMERVILLE, Mass., May 7, 2026 /PRNewswire/ -- Generate Biomedicines, Inc.   today reported financial results for the first quarter ended March 31, 2026, and highlighted progress across its clinical portfolio.Generate's GB-5267  program, developed in collaboration with Roswell Park Comprehensive Cancer Center, is expected to dose the first patient in the second half of 2026 in a Phase 1 clinical trial in solid tumors, initially targeting ovarian cancer.Cash, cash equivalents, and marketable securities were $516.6 million as of March 31, 2026, compared with $221.5 million as of December 31, 2025. The cash, cash equivalents, and marketable securities as of March 31, 2026, reflects $369.3 million in net proceeds from Generat","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENB","VIE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633122117","title":"Generate Biomedicines Q1 FY26 net loss widens to $61.7 million; revenue falls to $7.2 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633122117","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633122117?lang=en_us&edition=fundamental","pubTime":"2026-05-07 18:13","pubTimestamp":1778148829,"startTime":"0","endTime":"0","summary":"Generate Biomedicines posted a first-quarter net loss of $61.7 million, widening from $44.3 million a year earlier, as revenue slipped 18% to $7.2 million.Research and development expense climbed 24% to $57.8 million, driven by continued investment in the GB-0895 Phase 3 severe asthma program plus higher personnel-related costs.Cash, cash equivalents, and marketable securities jumped to $516.6 million as of March 31 from $221.5 million at year-end, reflecting $369.3 million in net IPO proceeds; runway seen into first half of 2028.GB-0895 Phase 3 SOLAIRIA-1 and SOLAIRIA-2 trials continued to advance, while GB-4362 clinical sites were activated with first patient dosing expected mid-2026 and GB-5267 first dosing expected in second half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL26sKRG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627243466","title":"Generate Biomedicines Initiated at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2627243466","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627243466?lang=en_us&edition=fundamental","pubTime":"2026-04-13 18:37","pubTimestamp":1776076620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GENB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 13, 2026 06:37 ET (10:37 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627043141","title":"Generate Biomedicines initiated with a Buy at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2627043141","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627043141?lang=en_us&edition=fundamental","pubTime":"2026-04-13 18:18","pubTimestamp":1776075525,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Generate Biomedicines (GENB) with a Buy rating and $16 price target The stock has fal...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/generate-biomedicines-initiated-with-a-buy-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/generate-biomedicines-initiated-with-a-buy-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GENB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626112969","title":"Buy Rating on Generate Biomedicines Driven by Differentiated Pipeline, GB-0895 Asthma Opportunity, and AI-Enabled Protein Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2626112969","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626112969?lang=en_us&edition=fundamental","pubTime":"2026-04-11 01:45","pubTimestamp":1775843123,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Salveen Richter from Goldman Sachs maintained a Buy rating on Generate Biomedicines, Inc., with a price target of $...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-on-generate-biomedicines-driven-by-differentiated-pipeline-gb-0895-asthma-opportunity-and-ai-enabled-protein-platform-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-on-generate-biomedicines-driven-by-differentiated-pipeline-gb-0895-asthma-opportunity-and-ai-enabled-protein-platform-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARTY","AGIX","AIPO","GENB","CHAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625494368","title":"Generate Biomedicines publishes corporate presentation on programmable biology drug design platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2625494368","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625494368?lang=en_us&edition=fundamental","pubTime":"2026-04-08 19:07","pubTimestamp":1775646420,"startTime":"0","endTime":"0","summary":"Generate Biomedicines outlined strategy to use generative biology and scaled lab automation to lower drug-discovery time to proof of concept to 3-5 years from 6-8 years.Company also projected cost to proof of concept of $25-60 million versus $380 million for traditional discovery.Lead program GB-0895, anti-TSLP monoclonal antibody, is positioned for twice-yearly dosing with reported human half-life of 98 days.GB-0895 is in Phase 3 development in severe asthma, with Phase 1b results in moderate-to-severe COPD slated for 1H 2026.Pipeline catalyst slate includes planned Phase 1 first-patient-dosed starts in 1H 2026 for GB-4362, an MMAE toxin neutralizer, in first-line metastatic urothelial cancer, alongside GB-5267 MUC-16 armored CAR-T in relapsed or refractory platinum-resistant ovarian cancer.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDL1MDjP1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622006872","title":"BUZZ-Morgan Stanley bullish on Generate Biomedicines, cites strength of lead asthma drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2622006872","media":"Reuters","labels":["shareholding","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622006872?lang=en_us&edition=fundamental","pubTime":"2026-03-26 01:52","pubTimestamp":1774461124,"startTime":"0","endTime":"0","summary":"BUZZ-Morgan Stanley bullish on Generate Biomedicines, cites strength of lead asthma drug** Morgan Stanley initiates drug developer Generate Biomedicines GENB.O with an \"overweight\" rating as research quiet period ends** Company secured a valuation of nearly $1.91 bln at open after its debut on the Nasdaq late last month** Brokerage cites, \"we see GENB's lead asset, GB-0895, as having best-in-class potential vs. blockbuster generating commercial benchmarks\"** GB-0895 is GENB's lead product to treat severe asthma which is being tested in a late-stage trial ** \"We believe GB-0895 has credible best-in-class potential in severe asthma by improving on a validated mechanism rather than reinventing the biology\"- MS** Goldman Sachs, Morgan Stanley, Piper Sandler, Guggenheim Securities and Cantor were the underwriters for GENB's offering** As of last close, stock down 24% since its debut on Feb. 27  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nL4N40D1S9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053671581.USD","GENB","PIPR","BK4127","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622077173","title":"Generate Biomedicines: Differentiated AI-Driven Protein Platform with GB-0895 Asthma Lead and Emerging Oncology Upside Justifies Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2622077173","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622077173?lang=en_us&edition=fundamental","pubTime":"2026-03-25 22:45","pubTimestamp":1774449917,"startTime":"0","endTime":"0","summary":"Salveen Richter, an analyst from Goldman Sachs, has initiated a new Buy rating on Generate Biomedicines, Inc. (GENB). Salveen Richter has given his...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/generate-biomedicines-differentiated-ai-driven-protein-platform-with-gb-0895-asthma-lead-and-emerging-oncology-upside-justifies-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/generate-biomedicines-differentiated-ai-driven-protein-platform-with-gb-0895-asthma-lead-and-emerging-oncology-upside-justifies-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CHAT","AIPO","GENB","AGIX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":56,"code":"91000000","status":"200"}]}}